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Natural history of non-bullous impetigo:
a systematic review of time to resolution or improvement without antibiotic 
treatment
INTRODUCTION
Antibiotics may make little clinical difference 
in many of the self-limiting infections with 
which patients present to general practice. 
Non-bullous impetigo (also known as 
school sores) is a common skin infection 
caused by bacteria such as Staphylococcus 
aureus and Streptococcus pyogenes, and is 
often treated with antibiotics, given either 
topically or orally.1 Common antibiotics 
used include fusidic acid, mupirocin, 
flucloxacillin, and clarithromycin. Rates 
of bacterial resistance to the antibiotics 
used to treat impetigo have been increasing 
worldwide.2,3 
The rationale for antibiotic use is that they 
are thought to reduce the risk of contagious 
spread within the patient and to others, 
speed up resolution of the lesions, and 
reduce the risk of complications such as 
rheumatic fever in vulnerable populations. 
However, these antibiotics may cause 
side effects, as well as contribute to the 
development of antibiotic resistance,4 and 
use should be limited where possible. The 
natural history of impetigo when antibiotics 
are not used is unclear.
Knowledge of the natural course of 
impetigo, including the likely duration 
of symptoms, can assist in informed 
decision making about management of 
the condition. This information can assist 
clinicians to engage with patients in shared 
decision making, and help them to have a 
better understanding of what may happen 
if antibiotics are not used compared with 
what happens if they are.3,5 This study aimed 
to review all published information available 
from placebo groups of randomised trials 
or from cohort studies about the time 
to resolution of non-bullous impetigo 
symptoms without antibiotic treatment.
METHOD
Eligibility criteria
The authors aimed to identify studies that 
met the following criteria:
• included children or adults who had non-
bullous impetigo; 
• reported outcome data on the clinical 
improvement and/or resolution of non-
bullous impetigo over time, and 
• included a group that received no 
therapeutic treatment (that is, placebo or 
‘no treatment’) — this could be either a 
comparison group in a randomised trial 
or a single-group prognosis study, such 
as a cohort study.
Search methods
A librarian experienced in systematic 
reviews conducted the search in PubMed up 
to 15 November 2018 to identify systematic 
reviews (as a method of identifying 
potentially eligible randomised trials) and 
prognosis studies (see Supplementary 
Box S1). A forward–backward citation 
analysis was also performed. An updated 
search was conducted on 28 January 2020, 
but found no further eligible studies.
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about antibiotic use.
Aim





The authors searched PubMed up to January 
2020, as well as reference lists of articles 
identified in the search. Eligible studies 
involved participants with impetigo in either 
the placebo group of randomised trials, or 
in single-group prognostic studies that did 
not use antibiotics and measured time to 
resolution or improvement. A modified version 
of a risk of bias assessment for prognostic 
studies was used. Outcomes were percentage 
of participants who had either symptom 
resolution, symptom improvement, or failed to 
improve at any timepoint. Adverse event data 
were also extracted.
Results
Seven randomised trials (557 placebo group 
participants) were identified. At about 7 days, 
the percentage of participants classified as 
resolved ranged from 13% to 74% across the 
studies, whereas the percentage classified as 
‘failure to improve’ ranged from 16% to 41%. 
The rate of adverse effects was low. Incomplete 
reporting of some details limited assessment 
of risk of bias.
Conclusion
Although some uncertainty around the 
natural history of non-bullous impetigo 
remains, symptoms resolve in some patients 
by about 7 days without using antibiotics, 
with about one-quarter of patients not 
improving. Immediate antibiotic use may 
not be mandatory, and discussions with 
patients should include the expected course of 
untreated impetigo and careful consideration 
of the benefits and harms of antibiotic use.
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Screening and eligibility assessment
One researcher screened the search results 
by title and abstract, and then checked 
the full text of potentially eligible articles; 
discussions with a second researcher about 
eligibility took place as needed. Three non-
English articles that were potentially eligible 
were translated for screening purposes 
using Google Translate (two were excluded 
at abstract level, and one after full-text 
check).
Risk of bias assessment and data 
extraction
As the authors were focused on using 
prognosis outcome data, they used a 
modified version of a risk of bias assessment 
framework proposed by Altman et al to 
assess the included studies.6 The study and 
methodological quality characteristics that 
were extracted were: country, sample size, 
age, inclusion criteria, exclusion criteria, 
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How this fits in 
Non-bullous impetigo is a very common 
reason for general practice consultation 
and antibiotic prescription. Informed 
decision making should consider the 
benefit–harm trade-off of antibiotic use 
and the natural course of the illness. Non-
bullous impetigo resolves spontaneously in 
some patients by about 7 days. Antibiotics 























Records identified through database
search (duplicates removed)
(n = 52)
• Search for prognosis studies (n = 32)
• Search for SRs containing RCTs (n = 20)  
Updated search in 2020
(duplicates removed)
(n = 10)
• Search for prognosis studies (n = 3)
• Search for SRs containing RCTs (n = 7)  
• Did not measure eligible
   outcomes (n = 13)
• Did not include a non-treatment
   group (n = 1)
• Ineligible population or study
   design (n = 29)
• SRs (n = 5)
• Primary studies (n = 4)
• SR articles removed after identifying
   RCTs (n = 5)
• Unable to obtain full text (n = 2)
Records screened by title and abstract
(n = 52)
Records screened by title and abstract
(n = 10)




• No placebo group (n = 3)
• No eligible outcomes (n = 3)
Articles excluded
(n = 6)
Articles for inclusion (n = 7) Articles for inclusion (n = 0)
Articles included in analysis
(n = 7)




identified in reference lists
of screened articles
(n = 1)




• Did not measure eligible
   outcomes (n = 6)
• Did not include a non-treatment
   group (n = 1)
• Ineligible population or study
   design (n = 3)
Records excluded
(n = 10)
Figure 1. Flow of articles through the review. 
RCT = randomised controlled trial. SR = systematic 
review. 
definition of ‘clinical cure’ and ‘failure to 
improve’, randomisation method, placebo, 
concurrent treatment, symptom duration 
before study inclusion, and duration of 
follow-up.
To obtain data regarding the proportion 
of symptom-free patients, the authors 
extracted data from the studies, either 
directly from the published text and tables or, 
where needed, by using extraction software 
(WebPlotDigitizer, https://automeris.io/
WebPlotDigitizer) to retrieve values from 
the figures. In trials in which participants’ 
symptoms worsened and they left the 
placebo group to commence antibiotics, 
the authors calculated the percentage 
outcome data by using the total number of 
participants that were initially randomised 
to the placebo group as the denominator, 
whenever it was possible to do so.
Outcomes
Data were extracted for the following 
outcomes from participants in the placebo 
group, along with the study authors’ 
definition of each:
• percentage of participants with resolved 
symptoms (‘clinical cure’) at any 
timepoint;
• percentage of participants clinically 
improved at any timepoint; and
• percentage of participants whose 
symptoms failed to improve (requiring 
antibiotics) at any timepoint.
Data were also extracted regarding the 
rate of crossover from placebo to antibiotic 
groups, reasons for the crossover, and 
adverse events within both treatment 
and placebo group participants. In some 
studies, percentage values were given for a 
time range (for example, x% symptom free 
at 7–9 days). In these cases, the median 
timepoint was used to present values 
graphically (for example, x% symptom free 
at 8 days).
Data analysis
Scatter plots of outcome data versus time 
were used to enable visualisation of the rate 
of symptom resolution. The diameter of the 
data points on the scatter plots represents 
each study’s sample size.
RESULTS
Figure 1 shows the flow of articles. The 
authors found 52 studies from the database 
searches and one additional study from 
citation searching of identified relevant 
studies. After full-text checking, seven 
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studies were included.7–13 The updated 
search conducted in January 2020 identified 
10 articles for screening, but no new eligible 
studies.
Characteristics of included studies
All studies were randomised controlled 
trials, with the size of the placebo groups 
ranging from 12 to 206 participants (see 
Supplementary Table S1). The age across 
studies ranged from infancy to 80 years, with 
three trials including only children. There 
were no common exclusion criteria across 
all studies, although most reported recent 
antibiotic use as a reason for exclusion. Two 
studies excluded participants with eczema. 
The criteria for assessing clinical cure 
varied; some studies required complete 
disappearance of skin changes, whereas 
others required only that lesions be dry. Two 
studies used a Skin Infection Rating Scale 
(SIRS) and required healed lesions, but 
allowed for limited ongoing skin changes.
The placebos used were topical creams 
(four studies), ointments (two studies), 
and an oral suspension (one study). In 
three studies, placebo group participants 
were also instructed to use a concomitant 
treatment (such as, povidone-iodine 
shampoo, hexachlorophene soap, and 
Castile bath soap), and one study had 
‘allowed treatments’ that participants could 
use, although these were not specified. 
Risk of bias of included studies
The risk of bias assessment is shown in 
Table 1. Most studies reported on at least 
two of the four criteria. Randomisation 
and blinding were variably and often 
incompletely reported, making the risk of 
potential selection and ascertainment bias 
difficult to determine.
Clinical resolution or clinical 
improvement over time
Eleven values for clinical resolution and 
six values for clinical improvement were 
extracted (see Supplementary Table S2 
and Figure 2). Most studies made an 
assessment around day seven (counting 
from the first clinical visit). At around day 
seven, the percentage of participants with 
clinical cure or improvement ranged from 
13% to 74%. As this wide range could be 
affected by the various definitions for ‘clinical 
cure’, data points in Figure 2 are colour 
coded to represent complete clearance 
(lesions resolved and no skin changes 
seen), infection clearance (lesions healed 
but skin changes may still be present), and 
intermediate clearance (difficult to tell from 
study definition if skin changes are present). 
This colour coding does not reveal a pattern 
of symptom resolution related to definition 
of ‘cure’/improvement. 
Failure to improve and adverse effects 
over time
Nine values for clinical failure to improve 
were extracted (see Supplementary 
Table S2 and Figure 3). Lines drawn from 
the 100% failure to improve mark at 0 days 
(the day of first clinical visit) to each data 
point help to visualise the resolution of 
symptoms among participants towards 
zero symptoms. Five values were measured 
6–8 days after the first clinical visit, when 
the lowest percentage of participants 
with failure to improve was 16% and the 
highest was 41%. The rate of crossover or 
commencement of antibiotics at 1 week 
was reported in four studies. No major 
adverse effects for placebo participants 
were reported in any study. 
Figure 2. Change over time in the percentage of placebo 
participants with clinical cure (blue circles) or clinical 
improvement (orange circles).a
aSize of circles corresponds to sample size of each 
study. Varied definitions of cure and improvement
as used are represented by: filled circle = complete 
skin resolution; empty circle = clearance of infection 
but skin changes can be present; partially filled circle 
= intermediate clearance. Dotted lines highlight the 
change from an initial 0% cure or improvement rate at 











































































Figure 3. Change over time in the percentage of placebo 
participants who ‘failed to improve’.a
aDotted lines highlight the change from an initial 100% 
‘failure rate’ at day 0 (see Supplementary Table S2).
DISCUSSION
Summary
The paucity of data for the natural history 
of impetigo has been noted previously.3 In 
this review, data from the placebo groups 
of seven randomised trials were used. No 
prognostic cohort studies were identified. 
For all studies, the focus of the outcome 
measurement timing was at or about 7 days. 
The percentage of participants classified 
as cured by about 7 days ranged from 
0% to 74% across the studies, with about 
half of the studies providing an estimate 
that approximately half of the participants 
were cured. Conversely, the percentage of 
participants who were classified as failure 
to improve by about 7 days ranged from 
16% to 41%, with three studies providing 
an estimate of about one-quarter of the 
participants.
Strengths and limitations
This review examined the natural history data 
for this condition that were available from 
placebo-controlled trials, a novel approach 
to providing prognostic information that is 
important for clinical decision making. It 
gives some evidence of what to expect when 
neither topical nor oral antibiotics are used. 
However, topical disinfectants were allowed 
in both intervention and placebo groups 
in four of the studies, which may have 
influenced the natural course of impetigo in 
cases where no intervention was used. 
A possible limitation is that the authors 
searched for systematic reviews as a 
method of identifying relevant randomised 
trials. This pragmatic approach was used 
because systematic reviews of trials 
of interventions for impetigo exist that 
would have already identified potentially 
eligible trials. Heterogeneity, such as in 
the definition of cured/healed lesions and 
timing of outcome measurement, precluded 
a meta-analysis being conducted. Other 
limitations in the available data include 
that the inclusion and exclusion criteria 
varied among the studies (for example, two 
studies included some bullous forms and 
not all explicitly excluded eczema, which 
can be difficult to distinguish from impetigo); 
duration of symptoms before inclusion in 
the study was unclear for all but two studies; 
and the use of concomitant treatments 
was allowed in four studies. Incomplete 
reporting of methods such as case selection 
and method of blinding for many studies 
limited assessment of prognosis-related 
risk of bias. 
Comparison with existing literature 
The opinion that impetigo lasts about 
2–3 weeks without treatment is provided in 
the introduction of a Cochrane systematic 
review of interventions for impetigo and in 
clinical guides,3,14 but this does not appear 
to be informed by research. The Cochrane 
review found that the cure rate in placebo 
groups at 7 days ranged from 0% to 42%.3 
The current review includes two more 
recent randomised trials, hence the higher 
cure rates in the range. Interpretation of 
‘clinical cure’ values is made difficult by 
the differences in the definition across the 
studies. Although some required a complete 
return to normal skin, others required 
only that the lesions be ‘inactive’, allowing 
for ongoing signs of skin inflammation. 
However, all definitions included the 
stipulation that the lesions be dry, and that 
exudate or pus should be absent.
Implications for research and practice
Certainty about the natural history of non-
bullous impetigo would be increased by 
additional primary research — ideally, 
rigorous studies with appropriate sample 
sizes, follow-up beyond the first week of 
symptoms, use of standardised outcome 
measure description and timing, and 
measurement of recurrence and spread to 
others such as family members.
This review provides some data showing 
that the use of antibiotics is not mandatory 
for patients with non-bullous impetigo. 
Information about the expected course of 
untreated impetigo may help patients and 
parents to frame their expectations about 
recovery timeframes. Even if a precise 
mean duration of time to healing is not 
available from existing data, the information 
presented may be useful for primary care 
clinicians to engage in shared decision 
making with patients (or their parents) 
about whether antibiotics should be used 
for the management of impetigo. Given 
the cure rates at 1 week suggested by 
this review, adopting a delayed prescribing 
approach to antibiotics may be appropriate 
for many patients with impetigo. None of the 
included studies reported serious adverse 
effects in the placebo group participants, 
and the rate of any minor adverse effects 
was low. In certain populations, non-
suppurative complications (for example, 
acute glomerulonephritis and acute 
rheumatic fever), which may be caused by 
Streptococcus, a common causative agent 
associated with impetigo, are more likely.15,16
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